SAN FRANCISCO, Oct. 24 – Genaissance Pharmaceuticals on Wednesday posted third-quarter revenues of $1.1 million compared to $67,000 for the same quarter a year ago, the company announced.

“We have made considerable progress in the year since we completed our IPO,” Gualberto Ruano said in a statement. “Our technology is the gold standard for identifying gene variation, and our clinical development efforts have resulted in the initiation of the largest prospective genomics clinical trials ever conducted to correlate our proprietary gene markers with drug response.”

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.